Krystal Biotech, Inc. Common Stock (KRYS) — Analysis Summary
Krystal Biotech, Inc. Common Stock (KRYS) has a market cap of $10.40B with year-over-year revenue growth of +33.9%. Net margin stands at 52.6%. The stock trades at a P/E ratio of 43.1.
Key Takeaways
- Revenue changed +33.9% year-over-year
- Net margin of 52.6%
- P/E ratio of 43.1
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, KRYS posted revenue growth of +33.9% and trades at a P/E of 43.1.
Krystal Biotech, Inc. Common Stock (KRYS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin (44.9%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
295
Headquarters
PITTSBURGH, PA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.